Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
Conventional systemic therapies can be highly risky or even contraindicated in elderly psoriatic patients, shifting physicians' attention to biologics1 . However, efficacy and safety of biologics in patients ≥65 years are not clearly described. Even if few data are available for anti-TNF-α and anti-IL12/23 use in geriatric patients1-6 more studies are needed for anti-IL-17.